PriceTargets.com logo

Enliven Therapeutics - ELVN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $75.44
  • Forecasted Upside: 70.50%
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$44.25 As of 10/30/2026 05:00 PM ET
▼ -0.83 (-1.84%)

This chart shows the closing price for ELVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enliven Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELVN

Analyst Price Target is $75.44
▲ +70.50% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Enliven Therapeutics in the last 3 months. The average price target is $75.44, with a high forecast of $82.00 and a low forecast of $70.00. The average price target represents a 70.50% upside from the last price of $44.25.

This chart shows the closing price for ELVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Enliven Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/19/2026HC WainwrightBoost TargetBuy ➝ Buy$65.00 ➝ $73.00
10/15/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/13/2026Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2026GuggenheimReiterated RatingBuy ➝ Buy
10/2/2026Morgan StanleyInitiated CoverageOverweight$70.00
10/1/2026JPMorgan Chase & Co.Initiated CoverageOverweight$75.00
8/18/2026William BlairInitiated CoverageOutperform
8/18/2026BarclaysInitiated CoverageOverweight$78.00
8/18/2026MizuhoBoost TargetOutperform ➝ Outperform$62.00 ➝ $73.00
8/6/2026GuggenheimLower TargetBuy ➝ Buy$80.00 ➝ $78.00
8/6/2026Stifel NicolausBoost TargetBuy ➝ Buy$80.00 ➝ $82.00
8/6/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$67.00 ➝ $80.00
7/21/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$59.00 ➝ $67.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/9/2026HC WainwrightBoost TargetBuy ➝ Buy$56.00 ➝ $64.00
7/1/2026Stifel NicolausBoost TargetBuy ➝ Buy$60.00 ➝ $80.00
6/29/2026JonesTradingBoost TargetBuy ➝ Buy$45.00 ➝ $70.00
6/9/2026Stifel NicolausInitiated CoverageBuy$60.00
6/2/2026MizuhoBoost TargetOutperform ➝ Outperform$45.00 ➝ $62.00
5/12/2026GuggenheimInitiated CoverageBuy$80.00
5/11/2026GuggenheimUpgradeStrong-Buy
5/8/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$41.00 ➝ $59.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/26/2026HC WainwrightBoost TargetBuy ➝ Buy$48.00 ➝ $56.00
3/25/2026MizuhoBoost TargetOutperform ➝ Outperform$41.00 ➝ $45.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/2/2025HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $48.00
6/16/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025The Goldman Sachs GroupInitiated CoverageBuy$37.00
5/16/2025JonesTradingLower TargetBuy ➝ Buy$36.00 ➝ $27.00
5/15/2025HC WainwrightBoost TargetBuy ➝ Buy$39.00 ➝ $40.00
3/21/2025HC WainwrightBoost TargetBuy ➝ Buy$37.00 ➝ $39.00
12/13/2024BTIG ResearchInitiated CoverageBuy$42.00
11/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$32.00 ➝ $40.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00
9/9/2024HC WainwrightInitiated CoverageBuy$37.00
6/11/2024Robert W. BairdUpgradeStrong-Buy
6/11/2024Robert W. BairdInitiated CoverageOutperform$32.00
4/9/2024MizuhoInitiated CoverageBuy$34.00
3/29/2023Jefferies Financial GroupInitiated CoverageBuy$27.00
3/7/2023Lifesci CapitalReiterated RatingOutperform
3/3/2023TD CowenInitiated CoverageOutperform
(Data available from 10/30/2021 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 3 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 11 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 11 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Enliven Therapeutics logo
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $44.25
Low: $44.09
High: $45.87

50 Day Range

MA: $48.70
Low: $37.32
High: $61.15

52 Week Range

Now: $44.25
Low: $14.78
High: $62.32

Volume

1,236,950 shs

Average Volume

1,600,464 shs

Market Capitalization

$3.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Enliven Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Enliven Therapeutics in the last year: Barclays PLC, Guggenheim, HC Wainwright, JonesTrading, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for ELVN.

What is the current price target for Enliven Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Enliven Therapeutics in the last year. Their average twelve-month price target is $75.44, suggesting a possible upside of 69.9%. Stifel Nicolaus has the highest price target set, predicting ELVN will reach $82.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $70.00 for Enliven Therapeutics in the next year.
View the latest price targets for ELVN.

What is the current consensus analyst rating for Enliven Therapeutics?

Enliven Therapeutics currently has 2 sell ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELVN.

What other companies compete with Enliven Therapeutics?

Other companies that are similar to Enliven Therapeutics include 4D Molecular Therapeutics, AbbVie, AbCellera Biologics, Abeona Therapeutics and Abivax. Learn More about companies similar to Enliven Therapeutics.

How do I contact Enliven Therapeutics' investor relations team?

Enliven Therapeutics' physical mailing address is 205 Park Road, Burlingame, CA, 94010. The company's listed phone number is (650) 547-5814 and its investor relations email address is [email protected]. The official website for Enliven Therapeutics is www.enliventherapeutics.com. Learn More about contacing Enliven Therapeutics investor relations.